Mozambique Pharmaceuticals & Healthcare Report

Published 12 February 2015

  • 55 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Mozambique Pharmaceuticals & Healthcare Report

BMI View: Mozambique ' s agricultural industry and natural resources contribute to its rapidly expanding economy, which will allow the Mozambican government to continue the development of healthcare infrastructure. The country ' s healthcare sector - which suffers from shortages of health professionals and poor access to treatment facilities - should begin to show signs of improvement with the help of foreign investment. However, previous risks to market growth remain as high levels of corruption, poor regulatory enforcement and political clashes will work to deter many multinational drug manufactures.

Headline Expenditure Forecasts

  • Pharmaceuticals: MZN6.86bn (USD221mn) in 2014 to MZN7.47bn (USD237mn) in 2015; +8.9% in local currency and +7.2% in US dollar terms.

  • Healthcare: MZN33.62bn (USD1.09bn) in 2014 to MZN37.37bn (USD1.19bn) in 2015; +11.2% in local currency and +9.4% in US dollar terms.

Risk/Reward Index

Mozambique has a score of 29.5 out of 100 in our Pharmaceutical Risk/Reward Index for Q215, marking no change from last quarter's score. However, the country has fallen one place, making it the 29th most attractive pharmaceutical market in the Middle East and Africa region. While the country is posting good economic growth, political unrest is emerging as well as outbreaks of violence.

Key Trends And Developments

January 2015

In the last five years 20% of HIV/AIDS patients have stopped receiving HIV/AIDS treatment in Mozambique, according to the National Council to Combat AIDS (CNCS). The long distance between patients' residences and treatment facilities was cited as a major reason for neglecting treatment, according to the Deputy Secretary of the CNCS Diogo Miracle. The secretary noted that to amend the situation, Plan HIV / AIDS 2015/19 aims to provide more health centres equipped with antiretroviral treatment. In addition, the strategy urges community leaders to raise awareness among the population for the prevention of disease, and to obey the...

Table of Contents

BMI Industry View
7
SWOT
9
Political
10
Economic
12
Business Environment
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Mozambique 2010-2018)
17
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2010-2018)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2010-2018)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2010-2018)
20
Key Risks To BMI's Forecast Scenario
21
Macroeconomic Forecasts
22
Economic Analysis
22
Table: Mozambique's GDP By Expenditure, 2011-2018
27
Industry Risk Reward Ratings
28
Middle East & Africa Risk/Reward Ratings
28
Mozambique Risk/Reward Ratings
36
Rewards
36
Risks
36
Market Overview
38
Industry Trends And Developments
40
Epidemiology
40
Clinical Trials
42
Regulatory Development
44
Regulatory Development
44
Intellectual Property Issues
45
Pricing Regime
45
Competitive Landscape
46
Domestic Industry
46
Company Developments
46
Company Profile
48
Sociedade Mo-ambicana de Medicamentos (SMM)
48
Demographic Forecast
50
Table: Mozambique's Population By Age Group, 1990-2020 ('000)
51
Table: Mozambique's Population By Age Group, 1990-2020 (% of total)
52
Table: Mozambique's Key Population Ratios, 1990-2020
53
Table: Mozambique's Rural And Urban Population, 1990-2020
53
Glossary
54
Methodology
56
Pharmaceutical Expenditure Forecast Model
56
Healthcare Expenditure Forecast Model
56
Notes On Methodology
57
Risk/Reward Ratings Methodology
58
Ratings Overview
59
Table: Pharmaceutical Risk/Reward Ratings Indicators
59
Indicator Weightings
60

The Mozambique Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Mozambique Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Mozambique pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Mozambique, to test other views - a key input for successful budgeting and strategic business planning in the Mozambican pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Mozambican pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Mozambique.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc